Allogeneic Cell Therapy Devices Market (By Therapy Type: Stem Cell Therapies, Non-stem Cell Therapies; By Therapeutic Area Hematological Disorders, Dermatological Disorders, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032
The global allogeneic cell therapy devices market size was estimated at USD 260.14 million in 2022 and is expected to reach around USD 2,476.57 million by 2032, registering a CAGR of 25.28% during the forecast period from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. allogeneic cell therapy devices market size was valued at USD 115.11 million in 2022 and is estimated to surpass around USD 1,095.88 million by 2032, growing at a CAGR of 25.28% from 2023 to 2032.
North America as held largest revenue share in allogeneic cell therapy devices in 2022. North America boasts consist one of world's most advanced healthcare infrastructures, including specialized hospitals, innovative research facilities, and well-developed regulatory frameworks. These factors provide a beneficial environment for the commercialization and development of allogeneic cell therapy devices across the region.
Asia-Pacific estimated to observe the fastest expansion in the allogeneic cell therapy devices market in 2022. This is because various countries in the Asia-Pacific region have been investing significantly in upgrading their healthcare infrastructure, including the development of cutting-edge research facilities and specialized treatment centers. This infrastructure supports the advancement of allogeneic cell therapies. Moreover, the region continues to invest in healthcare infrastructure and innovation, it is well-positioned to play a vital role in the future of allogeneic cell therapy devices across the Asia-Pacific region.
The European allogeneic cell therapy devices market is anticipated to grow at a high rate during the forecast period. This is due to the Europe's commitment to research, innovation, and regulatory support positions it as a key region for high growth in the allogeneic cell therapy devices market. As the field continues to advance, Europe is likely to play a pivotal role in shaping the future of cell therapy development and adoption.
The allogeneic cell therapy devices is a dynamic sector within the healthcare and biotechnology industries that includes manufacturing, development, and application of specific devices and technologies vital for allogeneic cell therapy. It comprise using donor-derived cells to treat various medical conditions, from cancer to autoimmune diseases.
The allogeneic cell therapy devices market involves a comprehensive array of equipment, including purification devices, bioreactors, cell culture systems, and cryopreservation tools, which are essential for the administration and production of these therapies.
The allogeneic cell therapy devices market significance lies in its impact to evolving the field of regenerative medicine by providing the infrastructure vital to harness the therapeutic potential of allogeneic cell therapies. Manufacturers within the market engage in research, development, and commercialization of these devices, addressing critical aspects such as scalability, quality control, and safety.
The allogeneic cell therapy devices market is expected to grow, driven by various factors such as the rising occurrence of chronic diseases such as autoimmune disorders, cancer, and degenerative conditions is driving the demand for innovative and effective treatment options. It offer a promising approach by harnessing the regenerative potential of donor cells to address these ailments.
In addition, innovation in biotechnology and manufacturing processes have paved the way for the growth of more standardized and accessible allogeneic cell therapy products. This has not only enhanced the quality and consistency of allogeneic cell therapies but has also made them more cost-effective, thereby increasing their availability to a larger patient population. Furthermore, healthcare providers and regulatory agencies are identifying the probable benefits of allogeneic cell therapies and are streamlining the approval and reimbursement processes. This has encouraged investment in research and development by pharmaceutical companies and biotechnology firms, fostering innovation in the field.
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 25.28% |
| Market Size in 2023 | USD 325.77 Million |
| Market Size by 2032 | USD 2,476.57 Million |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Therapy Type and By Therapeutic Area |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver
Increasing incidence of chronic diseases
Chronic diseases, such as cardiovascular diseases, diabetes, cancer, and neurodegenerative disorders, are striking a significant and rising burden on global healthcare systems. Allogeneic cell therapy delivers an approach to address these challenging conditions. Traditional treatment modalities often provide only symptomatic relief or temporary management, leaving a significant unmet medical need. Allogeneic cell therapies, derived from healthy donor cells, have the potential to target the root causes of these diseases, providing curative or disease-modifying effects.
Furthermore, healthcare providers and patients both are seeking advanced, innovative and additional effective treatment options. This growing demand is catalyzing investments in research and development, clinical trials, and manufacturing capabilities for allogeneic cell therapies. Moreover, regulatory agencies are recognizing the promise of these therapies, streamlining approval processes, and facilitating market entry.
For instance, in December 2022, BioCardia received approval for its stem cell implants designed to help rescue patients from heart failure from the FDA. According to the company, it offers a complete cell therapy solution for ischemic heart failure patients that involves both off the shelf and autologous allogeneic cell therapies. Thus, the increasing incidence of chronic diseases underscores the urgent need for transformative treatments, positioning the allogeneic cell therapy devices market as a pivotal player in the healthcare landscape.
Restraints
High development costs
The intricate and multifaceted nature of developing allogeneic cell therapies, from research and preclinical studies to clinical trials and commercialization, incurs substantial expenses. These costs may act as a deterrent to both emerging biotech firms and established pharmaceutical companies, restraining their capability to invest in and improve these therapies. In addition, the need for state-of-the-art facilities and equipment for cell culture, expansion, and manipulation is one of major cost driver, all of which require substantial capital investment. In addition, the recruitment and retention of specialized talent in the fields of cell biology, immunology, and bioprocessing further inflate operating costs.
Furthermore, the rigorous regulatory requirements imposed by health authorities, such as the FDA and EMA, necessitate extensive preclinical testing and rigorous clinical trials. These studies are not only resource-intensive but also time-consuming, delaying potential market entry and accruing additional costs. Moreover, manufacturing processes for allogeneic cell therapies must be developed with meticulous attention to quality control and consistency, further adding to expenses.
The need to establish robust supply chains, infrastructure, and logistics for the collection, processing, and distribution of donor cells also contributes to the financial burden. Thus, the formidable development costs associated with allogeneic cell therapy devices can inhibit market growth and accessibility. Finding innovative ways to reduce these costs, such as optimizing manufacturing processes or leveraging economies of scale, will be crucial to realizing the full potential of allogeneic cell therapies and making them more accessible to patients in need.
Opportunities
Rising government activities for improving healthcare insurance frameworks
Government strategies to improve healthcare affordability and accessibility are forming a favorable environment for the adoption of advanced medical treatments, including allogeneic cell therapies. Globally governments are gradually identifying innovative therapies to advance patient outcomes and decrease the long-term economic burden of chronic diseases. Therefore, various manufacturers are taking steps to incorporate these therapies into their healthcare insurance frameworks. This may include reimbursement policies and coverage expansions, making these innovative treatments more accessible to a broader patient population.
Furthermore, governments are investing in research and development, boosting partnerships with pharmaceutical companies and academic institutions to accelerate the development of allogeneic cell therapies. These collaborations may lead to the formation of further effective therapies and facilitate their market entry. Improved insurance frameworks also reduce the financial burden on patients, making allogeneic cell therapies a viable option for individuals who may not have been able to afford them otherwise. This broader patient access not only benefits the individuals but also fosters market growth and innovation as demand for these therapies increases. Thus, the alignment of government activities with the advancement of healthcare insurance frameworks is creating significant growth opportunities for the allogeneic cell therapy devices market.
Impact of COVID-19
The COVID-19 pandemic has had both positive and negative impacts on the allogeneic cell therapy devices market. Initially, the pandemic disrupted the healthcare industry as resources and attention were redirected toward combating the virus. This led to delays in clinical trials, reduced patient access to therapies, and supply chain disruptions, affecting the allogeneic cell therapy market negatively. However, several factors have also created opportunities for the market during the pandemic.
The focus on the development of vaccines and treatments for COVID-19 accelerated research in areas such as immunology and cell therapy, potentially benefiting allogeneic cell therapies in the long run. Moreover, the pandemic highlighted the need for innovative and resilient healthcare solutions, making the market more attractive to investors.
Furthermore, telemedicine and remote monitoring also gained prominence during the pandemic, creating a conducive environment for the adoption of allogeneic cell therapies, which often require ongoing patient monitoring and follow-up. In addition, governments and regulatory agencies recognized the importance of advanced therapies in pandemic preparedness and response, potentially leading to streamlined regulatory pathways and increased funding for cell therapy research. Thus, the COVID-19 pandemic initially disrupted the allogeneic cell therapy devices market, but it has also underscored the importance of innovative healthcare solutions, potentially driving future growth and innovation in the field.
According to the therapy type, the stem cell therapy type has held highest revenue share in 2022. This segment includes treatments that utilize stem cells, which have the unique ability to differentiate into various cell types. The dominance of the stem cell therapies segment in the allogeneic cell therapy devices market is due to the surging occurrence of target diseases that can be cured with such therapies. It primarily treats chronic diseases such as leukemia, lymphoma, blood cancers, and specified blood or autoimmune disorders.
The non-stem cell therapy type is anticipated to expand at a significantly CAGR during the projected period. This segment includes cell-based therapies that do not rely on stem cells. It includes treatments using differentiated cells or immune cells, such as T-cell therapies, dendritic cell therapies, islet cell transplantation, and chondrocyte therapies.
Based on the therapeutic area, the hematological disorders segment is anticipated to hold the largest market share in 2022. The incidence of hematological disorders continues to rise globally, necessitating more advanced and effective treatment options. This growing patient population contributes to the segment's market share. Moreover, hematological disorders, including leukemia and lymphoma, have a long history of being treated with allogeneic cell therapies, particularly hematopoietic stem cell transplantation (HSCT). These treatments have demonstrated effectiveness in replacing diseased or damaged blood cells with healthy donor cells.
On the other hand, the dermatological disorders is projected to grow at the fastest rate over the projected period. This is due to the surging awareness of allogeneic stem cell-based therapy products used to treat a various dermatological diseases such as, wound healing, skin aging, scar therapy, atopic dermatitis, autoimmune skin disorders, and others.
Segments Covered in the Report
By Therapy Type
By Therapeutic Area
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Allogeneic Cell Therapy Devices Market
5.1. COVID-19 Landscape: Allogeneic Cell Therapy Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Allogeneic Cell Therapy Devices Market, By Therapy Type
8.1. Allogeneic Cell Therapy Devices Market Revenue and Volume, by Therapy Type, 2023-2032
8.1.1. Stem Cell Therapies
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Non-stem Cell Therapies
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Allogeneic Cell Therapy Devices Market, By Therapeutic Area
9.1. Allogeneic Cell Therapy Devices Market Revenue and Volume, by Therapeutic Area, 2023-2032
9.1.1. Hematological Disorders
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Dermatological Disorders
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Others
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Allogeneic Cell Therapy Devices Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.1.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.1.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.1.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.2.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.2.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.2.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.3.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.3.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.4.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.4.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.5.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.5.3.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Therapy Type (2020-2032)
10.5.4.2. Market Revenue and Volume Forecast, by Therapeutic Area (2020-2032)
Chapter 11. Company Profiles
11.1. SSM Cardinal Glennon Children's Medical Center
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Cleveland Cord Blood Center
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Duke University School of Medicine
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. New York Blood Center
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Clinimmune Labs, University of Colorado Cord Blood Bank
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. MD Anderson Cord Blood Bank
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. LifeSouth Community Blood Centers, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bloodworks Northwest
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. JCR Pharmaceuticals Co., Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Sumitomo Pharma Co., Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
